These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 24064437

  • 1. Role of fidaxomicin for the treatment of Clostridium difficile infection.
    Juang P, Hardesty JS.
    J Pharm Pract; 2013 Oct; 26(5):491-7. PubMed ID: 24064437
    [Abstract] [Full Text] [Related]

  • 2. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Hardesty JS, Juang P.
    Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589
    [Abstract] [Full Text] [Related]

  • 3. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB, Czosnowski QA.
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [Abstract] [Full Text] [Related]

  • 4. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA.
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [Abstract] [Full Text] [Related]

  • 5. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW, Matthews SJ.
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [Abstract] [Full Text] [Related]

  • 6. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T, Huesgen E, Danziger L.
    Am J Health Syst Pharm; 2012 Jun 01; 69(11):933-43. PubMed ID: 22610025
    [Abstract] [Full Text] [Related]

  • 7. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M.
    Expert Opin Pharmacother; 2010 Jun 01; 11(9):1569-78. PubMed ID: 20446864
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections.
    Soriano MM, Liao S, Danziger LH.
    Expert Rev Anti Infect Ther; 2013 Aug 01; 11(8):767-76. PubMed ID: 23977933
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fidaxomicin, a new treatment for Clostridium difficile infections.
    Epstein L, Golan Y.
    Drugs Today (Barc); 2012 Feb 01; 48(2):101-8. PubMed ID: 22384450
    [Abstract] [Full Text] [Related]

  • 13. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
    Sullivan KM, Spooner LM.
    Ann Pharmacother; 2010 Feb 01; 44(2):352-9. PubMed ID: 20071495
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H, Tateda K, Yanagihara K, Kusachi S, Takesue Y, Miki T, Oizumi Y, Gamo K, Hashimoto A, Toyoshima J, Kato K.
    J Infect Chemother; 2018 Sep 01; 24(9):744-752. PubMed ID: 29934056
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.